Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
BGB-A425 is a humanized, immunoglobulin gamma-1 (IgG1)-variant monoclonal antibody against
TIM-3. Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody
against PD-1. This study tests the safety and anti-tumor effect of BGB-A425 in combination
with tislelizumab in participants with advanced solid tumors.